Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07262060

Improving Preterm Kidney Outcomes With Caffeine

This study is being done to see if additional caffeine citrate (20 milligrams per kilogram IV bolus) helps babies with low kidney oxygenation already being treated with caffeine citrate (20 milligrams per kilogram IV bolus on day of life (DOL) 1 followed by 8 milligrams per kilogram daily maintenance). The investigators hypothesize that additional caffeine will improve kidney oxygen levels, while not causing any brain injury, and may reduce rates of acute kidney injury compared to placebo. This study will take place in preterm babies born less than 30 weeks gestational age, with the intervention occurring between greater than 48 hours of age until DOL 14 and outcomes tracked until neonatal intensive care unit (NICU) discharge.

Recruiting

Interested in participating?

Request Info

Key information

Age range

12 hour–96 hour

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

UW Hospital and Clinics

Madison, Wisconsin, 53792, United States

Location status: Recruiting

About this study

The study population will consist of 114 preterm neonates born less than 30 weeks gestational age who have an intravenous (IV) line for which IV medications can be administered and who can have brain and kidney Near Infrared Spectroscopy (NIRS) monitoring.

Eligible participants will be enrolled between 12-96 hours of life after preterm birth and admission to the Meriter NICU. Baseline data will be collected and NIRS monitoring will be started when appropriate as determined by the team based on clinical guidelines and standard of care.

Those participants having kidney oxygenation less than 50 percent (and troubleshooting procedures have occurred and while ensuring brain oxygenation is not below 55 percent) after 48 hours and within the first 14 DOL will be randomized in a 1:1 manner to one of two treatment arms (Arm 1 and Arm 2).

  • Arm 1: IV caffeine citrate (20 mg/kg) (n = 51)
  • Arm 2: Placebo - same volume of 0.9% Sodium Chloride United States Pharmacopeia (USP) (n=51)

Those participants who do not develop kidney hypoxia during the first 14 DOL will be the normal kidney oxygenation control group and receive no intervention (Arm 3).

  • Arm 3: Normal Kidney oxygenation (no intervention) (Approximately n = 12)

Participant accrual will occur over 48 months. Participants will complete all study specific activities during the NICU hospitalization over the course of the first 28 DOL and clinical outcomes will be collected through NICU discharge or 6 months of age, whichever occurs first. Each participant will contribute blood specimens for creatinine and caffeine levels as well as approximately 20-40 urine samples for biomarker analysis.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Gestational age at birth between 23 0/7 and 29 6/7 weeks.
  • Able to have near-infrared spectroscopy (NIRS) monitoring of cerebral and kidney oxygenation.
  • Able to receive IV medications.
  • Indwelling umbilical arterial catheter (UAC), umbilical venous catheter (UVC), peripheral arterial line (PAL), or peripherally inserted central catheter (PICC) already in place that can draw blood.
  • Receiving caffeine at the time of enrollment
  • Have a birth parent who is at least 18 years old and have a parent or guardian who is able to provide parental permission in English or Spanish

Exclusion criteria

  • Known or suspected major congenital anomaly of the brain, heart, lungs or kidney (excluding UTD A1 pyelectasis).
  • Known or suspected chromosomal or genetic anomaly.
  • Not suitable for study participation due to other reasons at the discretion of the investigators.

Treatment and study plan

Caffeine citrate

Drug

intravenous (IV) caffeine citrate (20 milligrams per kilogram) followed by 8 milligrams per kilogram daily maintenance

Placebo

Drug

same volume of 0.9 percent Sodium Chloride United States Pharmacopeia (USP)

Other names: saline

Primary outcomes

  1. Proportion of Participants with Improvement in Kidney Oxygenation

    Time frame: Up to 3 hours post-intervention (Between days 1 and 17)

    In the 3 hours after receiving the intervention or placebo, participants have kidney oxygenation monitored. Improvement in oxygenation is defined as having 30 minutes where at least 90 percent of measured values are at least 50 percent.

Secondary outcomes

  1. Number of Days of Acute Kidney Injury (AKI)

    Time frame: 14 days after intervention

    AKI as defined by the Kidney Disease Improving Global Outcomes (KDIGO) foundation. Outcome is measured for the 14 days after intervention.

  2. Proportion of Participants with a Sustained Decrease in Cerebral Oxygenation

    Time frame: up to 3 hours post-intervention (Between days 1 and 17)

    In the 3 hours after receiving the intervention or placebo, participants have cerebral oxygenation monitored. A sustained decrease in cerebral oxygenation is defined as less than 60 percent oxygenation for at least 60 minutes.

Other outcomes

  1. Change in Urinary Biomarker Concentrations

    Time frame: baseline, day 17

  2. Rates of Brain Injury

    Time frame: up to 6 months

    Rates of Brain injury (Periventricular Leukomalacia (PVL) or Interventricular hemorrhage (IVH) on term corrected brain imaging prior to discharge in participants receiving additional caffeine compared to those receiving placebo.

  3. Rates of Abnormal General Movement Assessment (GMA)

    Time frame: up to 6 months

    Rates of abnormal GMA prior to discharge in participants receiving additional caffeine compared to those receiving placebo.

Study contacts

Contact information is provided by the study sponsor or research team.

Elena Alfaro, CCRP

CONTACT

[email protected]

(608) 890-0584

Sponsors and collaborators

Lead sponsor

University of Wisconsin, Madison

Other

Collaborators

  • Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Registry information

Official study title

Optimizing Caffeine Therapy for Hypoxia in Preterm Neonates: A Randomized Trial Assessing Efficacy, Acute Kidney and Brain Injury, Safety, and Pharmacokinetics

Important dates

Study start
2026
Primary completion
2030
Study completion
2030
First posted
Dec 3, 2025
Registry last updated
Jun 4, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.